The High Cost of Protectionism in Prescription Drugs #53,476

Print
Thursday, 12 August 2010 21:42

The NYT has a front page article on the enormous success in identifying biological markers for the development of Alzheimer's that resulted from a collaborative effort in which all data was made freely available. The article reports the assessment of the leading participants that this departure from normal practice allowed for much greater progress than would have otherwise been possible.

It would be useful if in this or other articles the NYT explored the implications of this experience for bio-medical research more generally. It suggests that if research was freely shared that scientists may be far more successful in developing new drugs and other treatments for medical conditions. An open system of research would require the elimination of patent protection, but this would also mean that drugs could sell at their competitive market price rather than at prices that are several hundred to several thousand percent above the free market price.